Alpha Polymorph™ screens—the earliest stable form screens in the industry—rapidly identify the most probable stable polymorph of a new chemical entity (NCE) using as little as 100 mg of material.
The outcome of a screen—the Alpha Polymorph™—is the the most developable crystalline form of an NCE.
Identifying the Alpha Polymorph™ at the earliest possible phase of development de-risks programs from discovery through to regulatory approval, as the stable form of an NCE has the lowest propensity to transform during scale-up, processing, formulation, and storage.
Leveraging The Solubility Company’s proprietary miniaturized SPA® platform for optimized solvent selection dramatically accelerates timelines and minimizes material consumption. Additionally, process chemists, formulators and analytical chemists benefit from early solubility insights for scale-up, formulation, and analytical method development.
Alpha Polymorph™ screens are exclusively available through The Solubility Company.
Screening the solubility landscape for oral and parenteral delivery of a candidate molecule across the whole solubility landscape—aqueous buffers, biorelevant media, solvents, complexation agents, surfactants, lipids, oils, suspending agents, and crystallization inhibitors—provides a comprehensive view of a molecule.
By evaluating solubility, dissolution, and logP from just one milligram of material, researchers can comprehensively fingerprint their NCE and confidently identify the best formulation strategies to deliver efficacy and safety.
This unique, miniaturized, and data-driven approach accelerates and ensures a streamlined transition through the preclinical pipeline.
Viikinkaari 4
00790 Helsinki
FINLAND
1 Broadway
Cambridge MA 01242
United States
Workshop: Mitigating Risk in Small Molecule Drug Development
6 February 2025, MassBioHub, Cambridge, MA